<DOC>
	<DOCNO>NCT01597817</DOCNO>
	<brief_summary>Atopic dermatitis ( AD ) chronic inflammatory skin disease characterize exacerbation remission intensely pruritic lesion variable location . AD may acute ( short-term severe ) predominantly redness , vesicle ooze , may chronic ( long-term ) scaling , skin thickening , alter pigmentation exaggerate surface marking . The condition affect mainly crease elbow knee , face neck , although affect part body . The severity AD variable , range localize mild scale generalize involvement whole body . Itching predominant symptom , induce vicious cycle scratching , lead skin damage . There tendency lifelong dry sensitive skin . Skin AD often colonize Staphylococcus aureus contribute perpetuate cutaneous inflammation . AD treatment base skin hydration , identification elimination flare factor , pharmacologic therapy . Biofunctional textile emerge new complementary tool . Chitosan natural polysaccharide vitro anti-microbial activity regenerate property . The investigator aim evaluate effect textile coat chitosan AD treatment well impact systemic inflammation skin microbiome . The investigator hypothesize use biofunctional textile coat chitosan improve severity AD , quality life diminish skin colonization Staphylococcus aureus skin mould , namely Malassezia .</brief_summary>
	<brief_title>Efficacy Safety Biofunctional Textile Management Atopic Dermatitis</brief_title>
	<detailed_description>This randomize controlled trial examine efficacy safety bio functional textile treatment atopic dermatitis ( AD ) . Atopic dermatitis subject randomize placebo active group ask wear cotton long sleeved shirt pant ( single cotton versus cotton coat chitosan ) pyjama night 2 month period . Atopic dermatitis define Haniffin Rafka criterion ( Rothe MJ et al 2006 ) - must three major criterion 1 . Pruritus 2 . Typical morphology distribution 1 . Flexural lichenification linearity adult 2 . Facial extensor involvement infant child 3 . Chronic chronically-relapsing dermatitis 4 . Personal family history atopy ( asthma , allergic rhinitis , atopic dermatitis ) OR three minor criterion : Xerosis , Ichthyosis , palmar hyperlinearity , keratosis pilaris , Immediate ( type I skin-test reactivity , raise serum IgE , early age onset , tendency toward cutaneous infection ( especially S aureus herpes simplex ) impair cell-mediated immunity , tendency toward non-specific hand foot dermatitis , nipple eczema , cheilitis , recurrent conjunctivitis , dennie-Morgan infraorbital fold , keratoconus , anterior subcapsular cataract , orbital darkening , facial pallor facial erythema , pityriasis alba , anterior neck fold , itch sweating , intolerance wool lipid solvent , perifollicular accentuation , food intolerance , course influence environmental emotional factor , white dermographism . PROCEDURES After screen , subject enter run period 2 week . Patients meet Hannifin Radjka criterion AD randomize chitosan free chitosan coat cotton long sleeved t-shirts pant . Intervention continue 2 month . The medical investigator blind intervention compare AD severity begin end study Study Schedule : Visit 0 : - Explain study protocol - Review medical history determine eligibility base inclusion/exclusion criterion . - Schedule visit 1 Visit 1 : - Provide write information study - Obtain signature potential subject write informed consent - Perform medical examination register SCORAD index - Answer Dermatology quality life questionnaire - Patients explain give diary symptom card - Perform skin swab determine area ( 25 cm2 occipital , interscapular , brachial popliteal area ) - Perform serum sample - Patients explain trial give Shirt pant - Surveillance medical care , require Visit 2 : - Review medical history include medication history - Perform medical examination register SCORAD index - Answer quality life questionnaire - Deliver diary symptom card - Perform skin swab determine area - Perform serum sample Visits perform appropriate medical setting . Each visit last approximately 45 min . Primary Outcomes 1 . Investigator rat eczema severity : clinical improvement measure SCORAD ( score severity AD ) ( initial versus final , % change ) . SCORAD compose three different domain ( A= extension B= intensity C = subjective symptom ) . To determine extent , sit affected eczema shade draw body . The rule 9 use calculate affect area ( A ) percentage whole body : Head neck 9 % Upper limbs 9 % , Lower limbs 18 % , Anterior trunk 18 % , Back 18 % 1 % genitals , palm back hand . The score area add . The total area ' A ' , possible maximum 100 % . A representative area eczema select . In area , intensity follow sign assess none ( 0 ) , mild ( 1 ) , moderate ( 2 ) severe ( 3 ) . : Redness , Swelling , Oozing /crusting Scratch mark , Skin thickening ( lichenification ) , Dryness ( assessed area inflammation ) .The intensity score add together give ' B ' ( maximum 18 ) . Subjective symptom i.e. , itch sleeplessness , score patient relative use visual analogue scale 0 itch ( sleeplessness ) 10 bad imaginable itch ( sleeplessness ) . These score add give ' C ' ( maximum 20 ) . 2 . Changes Quality life . Patients ask answer Portuguese version Dermatology Life Quality Index ( &gt; 16 year old ) childrenÂ´s Dermatology Quality Life Index ( 4-16 year old ) begin end study Secondary Outcomes 1 . Changes participant rat symptoms eczema : patient ask record severity score itchiness sleep disturbance previous day diary card ( 10 point scale 0-none 10-extreme ) 2 . Changes need eczema treatment : patient ask record use topical steroid , antihistamine , oral steroid immunosuppressive drug diary card . 3 . Immunological serum marker : change serum total IgE , specific IgE enterotoxin A , B , C TSST ( staphylococcus enterotoxin ) serum eosinophil cationic protein ( ECP ) , blood eosinophil , C reactive protein . Changes cytokine serum level ( RANTES , IL-31 , IL-18 , IL-16 ) . 4 . Changes skin microflora : characterize skin microflora 25 cm2 popliteal , brachial intertriginous area , interscapular occipital region determine change number colony form unit Staphylococcus aureus begin end study . 5 . Presence seven common filaggrin gene mutation include R501X c.2282del4 INVESTIGATIONAL PRODUCT Acquisition : Textiles provide textile enterprise Crispim e Abreu Lda . Formulation packaging , do usual textile . Chitosan coat chitosan free garment indistinguishable .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Chitosan</mesh_term>
	<criteria>clinical diagnosis Atopic Dermatitis old 12 year old specific form eczema contact eczema , seborrheic eczema , nummular eczema , occupational dermatitis , hand eczema systemic disease accompany immunological skin abnormality psoriasis ; clinically significant chronic infectious disease ( ) ( eg , HIV , hepatitis B C ) ; breastfeed , pregnant/intending become pregnant study ; participation clinical study ; part staff personnel involve study ; family member investigational/study staff .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>Eczema</keyword>
	<keyword>Textiles</keyword>
</DOC>